Schizophrenia Research
Volume 96, Issue 1 , Pages 25-33 , November 2007

Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis

  • Lisa J. Phillips

      Affiliations

    • Department of Psychology, University of Melbourne, VIC, 3010 Australia
    • Corresponding Author InformationCorresponding author. Tel.: +61 3 9326 4774; fax: +61 3 9326 7616.
    • ,
  • Patrick D. McGorry

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia
    • ,
  • Hok Pan Yuen

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia
    • ,
  • Janine Ward

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia
    • ,
  • Kerri Donovan

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia
    • ,
  • Daniel Kelly

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia
    • ,
  • Shona M. Francey

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia
    • ,
  • Alison R. Yung

      Affiliations

    • ORYGEN Research Centre, Locked Bag 10, Parkville VIC, 3052 Australia
    • Department of Psychiatry, University of Melbourne, VIC, 3010 Australia

Received 22 January 2007 ,Revised 17 May 2007 ,Accepted 20 May 2007.

References 

  1. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. fourth ed.. Washington: American Psychiatric Association; 1994;
  2. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1983;
  3. Cadenhead K. Vulnerability markers in the schizophrenia spectrum: implications for phenomenology, genetics and the identification of the schizophrenia prodrome. Psychiatr. Clin. North Am. 2002;25:837–853
  4. Erhart SM, Marder SR, Carpenter WT. Treatment of schizophrenia negative symptoms: future prospects. Schizophr. Bull. 2006;32:234–237
  5. Häfner H, Nowotny B, Loffler W, an der Heiden W, Maurer K. When and how does schizophrenia produce social deficits?. Eur. Arch. Psychiatry Clin. Neurosci. 1995;246:17–28
  6. Hamilton M. The assessment of anxiety states by rating. Br. J. Psychiatry. 1959;32:50–55
  7. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56–61
  8. Harrigan SM, McGorry PD, Krstev H. Does treatment delay in first-episode psychosis really matter?. Psychol. Med. 2003;33:97–110
  9. Harris MG, Henry LP, Harrigan SM, Purcell R, Schwartz OS, Farrelly SE, et al. The relationship between duration of untreated psychosis and outcome: an eight-year prospective study. Schizophr. Res. 2005;79:85–93
  10. Heinrichs D, Hanlon T, Carpenter W. The Quality of Life Scale: an instrument for rating the schizophrenia deficit syndrome. Schizophr. Bull. 1984;10:388–398
  11. Jablensky A. Prevalence and incidence of schizophrenia spectrum disorders: implications for prevention. Aust. N. Z. J. Psychiatry. 2000;34:S26–S34(Suppl)
  12. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. Biol. Psychiatry. 2006;59:97–105
  13. Kopala LC, Good KP, Milliken H, Buiteman C, Woodley H, Rui Q, et al. Treatment of a first episode of psychotic illness with quetiapine: an analysis of 2 year outcomes. Schizophr. Res. 2006;81:29–39
  14. Larsen TK. The transition from the premorbid period to psychosis: how can it be described?. Acta Psychiatr. Scand., Suppl. 2002;106:10–11
  15. Larsen TK, Melle I, Auestad B, Friis S, Haahr U, Johannessen JO, et al. Early detection of first-episode psychosis: the effect on 1-year outcome. Schizophr. Bull. 2006;32:758–764
  16. Manderscheid RW, Rae DS, Narrow WE, Locke BZ, Regier DA. Congruence of service utilization estimates from the Epidemiologic Catchment Area Project and other sources. Arch. Gen. Psychiatry. 1993;50:108–114
  17. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with ‘at-risk mental states’. Schizophr. Res. 2004;71:227–237
  18. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: I. Study rationale and design. Schizophr. Res. 2003;61:7–18
  19. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods S, et al. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatr. 2006;163:790–799
  20. McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, et al. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry. 2002;59:921–928
  21. McGorry PD, Yung AR, Phillips LJ. The ‘close-in’ or ultra high risk model: a safe and effective strategy for research and clinical intervention in prepsychotic mental disorder. Schizophr. Bull. 2003;29:771–790
  22. Meares A. The diagnosis of prepsychotic schizophrenia. Lancet. 1959;55–58
  23. Melle I, Johannesen JO, Friis S, Haahr U, Joa I, Larsen TK, et al. Early detection of the first episode of schizophrenia and suicidal behavior. Am. J. Psychiatr. 2006;163:800–804
  24. Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, et al. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis: II Baseline characteristics of the ‘prodromal’ sample. Schizophr. Res. 2003;61:19–30
  25. Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, et al. Cognitive therapy for the prevention of psychosis in people at ultra-high risk. Br. J. Psychiatry. 2004;185:291–297
  26. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:799–812
  27. Phillips LJ, Francey SM. Changing PACE: psychological interventions in the pre-psychotic phase. In:  McGorry PD,  Gleeson J editor. Psychological Interventions in Early Psychosis: A Practical Treatment Handbook. Chichester: John Wiley & Sons; 2004;p. 23–40
  28. Phillips LJ, Leicester SB, O'Dwyer LE, Francey SM, Koutsogiannis J, Abdel-Baki A, et al. The PACE Clinic: identification and management of young people at 'ultra' high risk of psychosis. J. Psychiatr. Pract. 2002;8:255–269
  29. Sullivan HS. The onset of schizophrenia. Am. J. Psychiatr. 1927;151:135–139(reprinted 1994)
  30. Tarrier N, Haddock G, Lewis S, Drake R, Gregg L SoCRATES Trial Group. Suicide behaviour over 18 months in recent onset schizophrenic patients: the effects of CBT. Schizophr. Res. 2006;83:15–27
  31. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry. 1978;133:429–435
  32. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring and care of young people at incipient risk of psychosis. Schizophr. Bull. 1996;22:283–303
  33. Yung AR, Phillips LJ, Yuen HP, McGorry PD, Francey SF, McFarlane CA. Psychosis prediction: 12 month follow-up of a high risk (‘prodromal’) group. Schizophr. Res. 2003;60:21–32
  34. Yung AR, Phillips LJ, McGorry PD. Treating Schizophrenia in the Prodromal Phase. London: Taylor & Francis; 2004;
  35. Yung AR, Phillips LJ, Yuen HP, McGorry PD. Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004;67:131–142

PII: S0920-9964(07)00240-X

doi: 10.1016/j.schres.2007.05.018

Schizophrenia Research
Volume 96, Issue 1 , Pages 25-33 , November 2007

Article Tools

* Image Usage & Resolution